FeesSafety
Pluang+

SpyGlass Pharma reports strong Q3 2026 with 4-year glaucoma drug data and new manufacturing capacity.

Company Fundamentals
11 Nov 2026, 23:05 WIB
GlobeNewsWire
View Source
Bullish
SpyGlass Pharma reports strong Q3 2026 with 4-year glaucoma drug data and new manufacturing capacity.

SpyGlass Pharma announced Q3 2026 results highlighting a $215.8M cash reserve and progress in glaucoma treatments. They acquired Advanced Vision Science to secure manufacturing for their BIM-IOL System, which showed a 37% reduction in eye pressure and 86% of patients off eye drops after four years in trials. Enrollment in Phase 3 trials continues on schedule, with completion expected in 2027. The company also initiated first implantations of a new drug delivery system, BIM-DRS, designed for up to seven years of treatment.

SpyGlass Pharma's $215.8 million cash reserve stands out as a key figure amid its Q3 2026 financial results and corporate updates. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 04:11 WIB: out of 150 priced US health stocks, 87 rose and 61 fell. Notable movers include NUWE at USD 5.58 with a 6.49% increase and 100% sell order activity, NVAX at USD 10.20 down 6.34% with 83% sell orders, and TNGX at USD 25.83 up 6.30% with balanced buy/sell activity.

More News

AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment wins $405M order for laser systems to boost Middle East counter-drone defense

AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...

Market News
Bullish
49 minutes ago
Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Q3 2026 earnings and revenue miss estimates, shares fall and guidance is cut

Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...

Company Fundamentals
Bearish
53 minutes ago
Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

Global beverage market to reach $2.78T by 2032, driven by nonalcoholic drinks and convenience trends.

The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...

Market News
Bullish
3 hours ago
Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

Over 200 GLP-1 and incretin therapies in development are reshaping diabetes and obesity treatment landscapes.

DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...

Bullish
3 hours ago
Tennessee American Water issues over $84 in PFAS settlement credits per customer

Tennessee American Water issues over $84 in PFAS settlement credits per customer

Tennessee American Water has applied an additional $13.07 credit to customer accounts, bringing total PFAS settlement refunds to over $84 per customer. This credit follows approval from the Tennessee Public Utility Commission, allowing the company to...

Market News
Bullish
5 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App